SARS-CoV-2 and Multisystem Inflammatory Syndrome In Children (MIS-C)

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• The novel SARS-CoV-2 virus, identified in 2019, impacts children globally.
• While most pediatric SARS-CoV-2 infections are mild or asymptomatic, a subset develops Multisystem Inflammatory Syndrome in Children (MIS-C).
• MIS-C, first described in 2020, is a serious post-infectious inflammatory condition.

Purpose of the Study:

• To summarize the current understanding of Multisystem Inflammatory Syndrome in Children (MIS-C).
• To outline the presentation, evaluation, and management strategies for MIS-C.
• To highlight advancements in the scientific community's knowledge regarding MIS-C.

Main Methods:

• Literature review of studies on MIS-C.
• Analysis of clinical data regarding MIS-C presentation and outcomes.
• Synthesis of current treatment and management guidelines for MIS-C.

Main Results:

• MIS-C is a significant, albeit rare, post-infectious complication in children infected with SARS-CoV-2.
• Significant progress has been made in characterizing the clinical features of MIS-C.
• Established protocols exist for the evaluation and management of MIS-C.

Conclusions:

• The scientific community has rapidly increased its knowledge of MIS-C since its emergence.
• Effective strategies for the diagnosis and treatment of MIS-C are available.
• Continued research is vital for further understanding and managing MIS-C in pediatric populations.